Baxter International/Stuart Medical
This article was originally published in The Gray Sheet
Terminate negotiations over Baxter's acquisition of Stuart's medical supply division. According to a Feb. 19 Baxter press release, "the companies were unable to agree on the terms of the definitive agreement." Baxter had announced in November that it reached an agreement in principle to acquire the supply business for 6.5 mil. shares of its common stock and the assumption of $155 mil. of Stuart debt ("The Gray Sheet" Nov. 23, I&W-9).
You may also be interested in...
House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”